Molecular histology of lung cancer: From targets to treatments

Cancer Treatment Reviews

Volumn 41, Issue 4, 2015, Pages 361-375

  Wood, Steven L ^a   Pernemalm, Maria ^a,b   Crosbie, Philip A ^a   Whetton, Anthony D ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Biomarkers; Cancer stem cells; Epidermal growth factor receptor (EGFR); Lung cancer; Molecular histology; Personalised medicine

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; AFATINIB; CABOZANTINIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CRIZOTINIB; DACOMITINIB; DACTOLISIB; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GEMCITABINE; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; ONARTUZUMAB; PACLITAXEL; PILARALISIB; PROTEIN KINASE C; PROTEIN TYROSINE KINASE INHIBITOR; RILOTUMUMAB; SCATTER FACTOR RECEPTOR; SORAFENIB; TIVANTINIB; VANDETANIB; VOXTALISIB; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

ALTERNATIVE RNA SPLICING; CANCER PROGNOSIS; CANCER STEM CELL; CANCER SURVIVAL; CARCINOGENESIS; CIRCULATING TUMOR CELL; DISEASE COURSE; DNA SEQUENCE; ETHNIC DIFFERENCE; GENE DOSAGE; GENE FUSION; GENE MUTATION; GENE SEQUENCE; HIGH THROUGHPUT SEQUENCING; HISTOLOGY; HUMAN; LUNG CANCER; MICROMETASTASIS; MOLECULAR MECHANICS; NON SMALL CELL LUNG CANCER; NONHUMAN; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REVIEW; SIGNAL TRANSDUCTION; SMALL CELL LUNG CANCER; SOMATIC MUTATION; SQUAMOUS CELL LUNG CARCINOMA; SURVIVAL RATE; DRUG EFFECTS; GENETICS; LUNG NEOPLASMS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PERSONALIZED MEDICINE; PROCEDURES; PROGNOSIS;

HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; NEOPLASTIC STEM CELLS; PROGNOSIS; SIGNAL TRANSDUCTION;

EID: 84926251392     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2015.02.008     Document Type: Review

References (216)

1. Ginsberg M.S., Grewal R.K., Heelan R.T. Lung cancer. Radiol Clin North Am 2007, 45(1):21-43.
2. Novaes F.T., et al. Lung cancer: histology, staging, treatment and survival. J Bras Pneumol 2008, 34(8):595-600.
3. Youlden D.R., Cramb S.M., Baade P.D. The international epidemiology of lung cancer: geographical distribution and secular trends. J Thorac Oncol 2008, 3(8):819-831.
4. Campana D. Minimal residual disease in acute lymphoblastic leukemia. Hematol Am Soc Hematol Educ Program 2010, 2010:7-12.
5. Fullwood M.J., et al. Next-generation DNA sequencing of paired-end tags (PET) for transcriptome and genome analyses. Genome Res 2009, 19(4):521-532.
6. Baslan T., et al. Genome-wide copy number analysis of single cells. Nat Protoc 2012, 7(6):1024-1041.
7. Marguerat S., Bahler J. RNA-seq: from technology to biology. Cell Mol Life Sci 2010, 67(4):569-579.
8. Cowell J.K., Hawthorn L. The application of microarray technology to the analysis of the cancer genome. Curr Mol Med 2007, 7(1):103-120.
9. Liang S., et al. Quantitative proteomics for cancer biomarker discovery. Comb Chem High Throughput Screening 2012, 15(3):221-231.
10. Aebersold R., Mann M. Mass spectrometry-based proteomics. Nature 2003, 422(6928):198-207.
11. Walther T.C., Mann M. Mass spectrometry-based proteomics in cell biology. J Cell Biol 2010, 190(4):491-500.
12. Dunn W.B., et al. Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat Protoc 2011, 6(7):1060-1083.
13. Becker S., et al. LC-MS-based metabolomics in the clinical laboratory. J Chromatogr B Analyt Technol Biomed Life Sci 2012, 883-884:68-75.
14. Malet-Martino M., Holzgrabe U. NMR techniques in biomedical and pharmaceutical analysis. J Pharm Biomed Anal 2011, 55(1):1-15.
15. Kan Z., et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 2010, 466(7308):869-873.
16. Imielinski M., et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012, 150(6):1107-1120.
17. Mass Genomics. Mass Genomics: Medical genomics in the post-genome era. Mass Genomics 2010; Available from: <>. http://massgenomics.org/2010/07/somatic-mutations-in-four-human-cancers.html.
18. Sullivan I., et al. Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Lett 2014, 353(2):160-166.
19. Lunn R.M., et al. XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis 2000, 21(4):551-555.
20. Wang L.E., et al. Genome-wide association study reveals novel genetic determinants of DNA repair capacity in lung cancer. Cancer Res 2012.
21. Hamdi M., et al. DNA damage in transcribed genes induces apoptosis via the JNK pathway and the JNK-phosphatase MKP-1. Oncogene 2005, 24(48):7135-7144.
22. Couraud S., et al. Lung cancer in never smokers - a review. Eur J Cancer 2012, 48(9):1299-1311.
23. Belinsky S.A., et al. Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res 2006, 66(6):3338-3344.
24. Leng S., et al. Defining a gene promoter methylation signature in sputum for lung cancer risk assessment. Clin Cancer Res 2012, 18(12):3387-3395.
25. Belinsky S.A., et al. Gene promoter methylation in plasma and sputum increases with lung cancer risk. Clin Cancer Res 2005, 11(18):6505-6511.
26. Millares L., et al. Variability in the measurement of the methylation status of lung cancer-related genes in bronchial secretions. Oncol Rep 2014, 32(4):1435-1440.
27. Awad M.M., et al. Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med 2013, 368(25):2395-2401.
28. Katayama R., et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med 2012, 4(120):120ra17.
29. Camidge D.R., et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012, 13(10):1011-1019.
30. Shaw A.T., et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009, 27(26):4247-4253.
31. Li Y., et al. Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer. PLoS One 2013, 8(1):e52093.
32. Takeuchi K., et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012, 18(3):378-381.
33. Lira M.E., et al. Multiplexed gene expression and fusion transcript analysis to detect ALK fusions in lung cancer. J Mol Diagn 2012.
34. Shaw A.T., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013, 368(25):2385-2394.
35. Maniatis T., Tasic B. Alternative pre-mRNA splicing and proteome expansion in metazoans. Nature 2002, 418(6894):236-243.
36. Black D.L. Mechanisms of alternative pre-messenger RNA splicing. Annu Rev Biochem 2003, 72:291-336.
37. Xi L., et al. Whole genome exon arrays identify differential expression of alternatively spliced, cancer-related genes in lung cancer. Nucleic Acids Res 2008, 36(20):6535-6547.
38. Weir B.A., et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007, 450(7171):893-898.
39. Kim S.C., et al. A high-dimensional, deep-sequencing study of lung adenocarcinoma in female never-smokers. PLoS One 2013, 8(2):e55596.
40. Pietanza M.C., Ladanyi M. Bringing the genomic landscape of small-cell lung cancer into focus. Nat Genet 2012, 44(10):1074-1075.
41. Zimmermann S., Peters S. Going beyond EGFR. Ann Oncol 2012, 23(Suppl 10):x197-203.
42. Qu Y., et al. Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models. J Exp Clin Cancer Res 2014, 33:52.
43. Janne P.A., et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 2013, 14(1):38-47.
44. Heist, RS Combination of a MEK inhibitor, pimasertib (MSC1936369B), and a PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib dose-escalation trial. Subcategory: 2013; ASCO Abstract 2013]. Available from: <>. http://meetinglibrary.asco.org/content/112823-132.
45. Hata A.N., et al. Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers. Cancer Res 2014, 74(11):3146-3156.
46. Smit E.F., et al. Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report. J Thorac Oncol 2010, 5(5):719-720.
47. Groenendijk F.H., et al. Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation. Int J Cancer 2014.
48. Pao W., et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005, 2(1):e17.
49. Takezawa K., et al. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov 2012, 2(10):922-933.
50. Yang Y., et al. A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras. Mol Cancer Ther 2008, 7(4):952-960.
51. Webb C.P., et al. Evidence for a role of Met-HGF/SF during Ras-mediated tumorigenesis/metastasis. Oncogene 1998, 17(16):2019-2025.
52. Molina-Arcas M., et al. Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3-kinase in KRAS mutant lung cancer. Cancer Discov 2013.
53. Rosell R., et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009, 361(10):958-967.
54. Xu J., et al. Somatic mutation analysis of EGFR, KRAS, BRAF and PIK3CA in 861 patients with non-small cell lung cancer. Cancer Biomark 2011, 10(2):63-69.
55. Girard N., et al. Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma. Eur Respir J 2012, 39(2):366-372.
56. Mok T.S., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361(10):947-957.
57. Fukuoka M., et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011, 29(21):2866-2874.
58. Maemondo M., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362(25):2380-2388.
59. Inoue A., et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol 2013, 24(1):54-59.
60. Lee J.S., et al. Vandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol 2012, 30(10):1114-1121.
61. Wu Y.L., et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 2014, 15(2):213-222.
62. Yang J.C., et al. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013, 31(27):3342-3350.
63. Hirsh V., et al. Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1). J Thorac Oncol 2013, 8(2):229-237.
64. Katakami N., et al. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol 2013, 31(27):3335-3341.
65. Yang J.C., et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol 2012, 13(5):539-548.
66. Pao W., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004, 101(36):13306-13311.
67. Lynch T.J., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350(21):2129-2139.
68. Paez J.G., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304(5676):1497-1500.
69. Tokumo M., et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 2005, 11(3):1167-1173.
70. Cappuzzo F., et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005, 97(9):643-655.
71. Mitsudomi T., Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 2007, 98(12):1817-1824.
72. Kobayashi S., et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005, 352(8):786-792.
73. Pao W., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005, 2(3):e73.
74. Sharma S.V., et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007, 7(3):169-181.
75. Hammond D.E., et al. Quantitative analysis of HGF and EGF-dependent phosphotyrosine signaling networks. J Proteome Res 2010, 9(5):2734-2742.
76. Sequist L.V., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011, 3(75):75ra26.
77. Yoshimoto A., et al. Remarkable effect of gefitinib retreatment in a patient with nonsmall cell lung cancer who had a complete response to initial gefitinib. Am J Med Sci 2007, 333(4):221-225.
78. Miller V.A., et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012, 13(5):528-538.
79. Choi Y.L., et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010, 363(18):1734-1739.
80. Sasaki T., et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res 2011, 71(18):6051-6060.
81. Katayama R., et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci USA 2011, 108(18):7535-7540.
82. Toschi L., Janne P.A. Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer. Clin Cancer Res 2008, 14(19):5941-5946.
83. Chen Z., et al. Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. Cancer Res 2010, 70(23):9827-9836.
84. Sang J., et al. Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov 2013, 3(4):430-443.
85. Sequist L.V., et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol 2010, 28(33):4953-4960.
86. Ji C., et al. Induction of autophagy contributes to crizotinib resistance in ALK-positive lung cancer. Cancer Biol Ther 2014, 15(5):570-577.
87. Frampton J.E. Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer. Drugs 2013, 73(18):2031-2051.
88. Awad M.M., Engelman J.A., Shaw A.T. Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med 2013, 369(12):1173.
89. Esfahani K., Agulnik J.S., Cohen V. A systemic review of resistance mechanisms and ongoing clinical trials in ALK-rearranged non-small cell lung cancer. Front Oncol 2014, 4:174.
90. Casanovas O. The adaptive stroma joining the antiangiogenic resistance front. J Clin Invest 2011, 121(4):1244-1247.
91. Cascone T., et al. Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma. J Clin Invest 2011, 121(4):1313-1328.
92. Stinchcombe T.E. Targeted therapies for locally advanced or metastatic squamous cell carcinoma of the lung. Curr Treat Options Oncol 2013, 14(4):568-579.
93. Kim Y., et al. Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients. J Clin Oncol 2014, 32(2):121-128.
94. Sun Z., et al. New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer. Anticancer Drugs 2014.
95. Hammerman P.S., et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov 2011, 1(1):78-89.
96. Lazar V., et al. Integrated molecular portrait of non-small cell lung cancers. BMC Med Genomics 2013, 6:53.
97. Liu Y., et al. Muolecular impact of bone morphogenetic protein 7, on lung cancer cells and its clinical significance. Int J Mol Med 2012, 29(6):1016-1024.
98. Sriram K.B., et al. Array-comparative genomic hybridization reveals loss of SOCS6 is associated with poor prognosis in primary lung squamous cell carcinoma. PLoS One 2012, 7(2):e30398.
99. Bayle J., et al. Suppressor of cytokine signaling 6 associates with KIT and regulates KIT receptor signaling. J Biol Chem 2004, 279(13):12249-12259.
100. Krebs D.L., et al. SOCS-6 binds to insulin receptor substrate 4, and mice lacking the SOCS-6 gene exhibit mild growth retardation. Mol Cell Biol 2002, 22(13):4567-4578.
101. He B., et al. SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci USA 2003, 100(24):14133-14138.
102. Song L., et al. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene 2003, 22(27):4150-4165.
103. Hodge D.R., Hurt E.M., Farrar W.L. The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 2005, 41(16):2502-2512.
104. Kettunen E., et al. Differentially expressed genes in nonsmall cell lung cancer: expression profiling of cancer-related genes in squamous cell lung cancer. Cancer Genet Cytogenet 2004, 149(2):98-106.
105. Wikman H., et al. Identification of differentially expressed genes in pulmonary adenocarcinoma by using cDNA array. Oncogene 2002, 21(37):5804-5813.
106. Ekman S., et al. Clinical phase I study with an insulin-like growth factor-1 receptor inhibitor: experiences in patients with squamous non-small cell lung carcinoma. Acta Oncol 2011, 50(3):441-447.
107. Langer C.J., et al. Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer. J Clin Oncol 2014, 32(19):2059-2066.
108. Vincent E.E., et al. Targeting non-small cell lung cancer cells by dual inhibition of the insulin receptor and the insulin-like growth factor-1 receptor. PLoS One 2013, 8(6):e66963.
109. Comprehensive genomic characterization of squamous cell lung cancers Nature 2012, 489(7417):519-525.
110. Pirker R., et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 2012, 13(1):33-42.
111. Spigel D.R., et al. Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 2013, 31(32):4105-4114.
112. Turner N., Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010, 10(2):116-129.
113. Day E., et al. Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. Eur J Pharmacol 2008, 599(1-3):44-53.
114. Barrett C.L., et al. Transcriptome sequencing of tumor subpopulations reveals a spectrum of therapeutic options for squamous cell lung cancer. PLoS One 2013, 8(3):e58714.
115. Dash R., et al. Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity. Proc Natl Acad Sci USA 2011, 108(21):8785-8790.
116. Pierce A., et al. Identification of nuclear protein targets for six leukemogenic tyrosine kinases governed by post-translational regulation. PLoS One 2012, 7(6):e38928.
117. Rudin C.M., et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet 2012, 44(10):1111-1116.
118. Shimamura T., et al. Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer. Clin Cancer Res 2013, 19(22):6183-6192.
119. Wegner M. SOX after SOX: SOXession regulates neurogenesis. Genes Dev 2011, 25(23):2423-2428.
120. Xu C., et al. Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. Cancer Cell 2014, 25(5):590-604.
121. Helin K., et al. Loss of the retinoblastoma protein-related p130 protein in small cell lung carcinoma. Proc Natl Acad Sci USA 1997, 94(13):6933-6938.
122. Sarvesvaran J., et al. Is small cell lung cancer the perfect target for anti-telomerase treatment?. Carcinogenesis 1999, 20(8):1649-1651.
123. Rohr U.P., et al. Expression of the tyrosine kinase c-kit is an independent prognostic factor in patients with small cell lung cancer. Int J Cancer 2004, 111(2):259-263.
124. Takahashi T., et al. The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern. Oncogene 1991, 6(10):1775-1778.
125. Kim Y.H., et al. Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification. Oncogene 2006, 25(1):130-138.
126. Rygaard K., Nakamura T., Spang-Thomsen M. Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor, in SCLC cell lines and xenografts. Br J Cancer 1993, 67(1):37-46.
127. Cirocchi R., et al. Efficacy of surgery and imatinib mesylate in the treatment of advanced gastrointestinal stromal tumor: a systematic review. Tumori 2010, 96(3):392-399.
128. Johnson B.E., et al. Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res 2003, 9(16 Pt 1):5880-5887.
129. Schneider B.J., et al. Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung cancer. Clin Lung Cancer 2010, 11(4):223-227.
130. Dy G.K., et al. A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Ann Oncol 2005, 16(11):1811-1816.
131. Byers L.A., et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov 2012, 2(9):798-811.
132. Wang X., et al. Differential effects of camptothecin derivatives on topoisomerase I-mediated DNA structure modification. Biochemistry 1998, 37(26):9399-9408.
133. Meisenberg C., et al. TDP1/TOP1 ratio as a promising indicator for the response of small cell lung cancer to topotecan. J Cancer Sci Ther 2014, 6(7):258-267.
134. Murtaza M., et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013, 497(7447):108-112.
135. Crowley E., et al. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol 2013, 10(8):472-484.
136. Newman A.M., et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 2014, 20(5):548-554.
137. Kumar S., et al. Efficacy of circulating plasma DNA as a diagnostic tool for advanced non-small cell lung cancer and its predictive utility for survival and response to chemotherapy. Lung Cancer 2010, 70(2):211-217.
138. Board R.E., et al. Isolation and extraction of circulating tumor DNA from patients with small cell lung cancer. Ann N Y Acad Sci 2008, 1137:98-107.
139. Qiu M., et al. Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2015, 24(1):206-212.
140. Vinayanuwattikun C., et al. Epithelial-specific methylation marker: a potential plasma biomarker in advanced non-small cell lung cancer. J Thorac Oncol 2011, 6(11):1818-1825.
141. Ruchusatsawat K., et al. SHP-1 promoter 2 methylation in normal epithelial tissues and demethylation in psoriasis. J Mol Med (Berl) 2006, 84(2):175-182.
142. Lui Y.Y., et al. Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation. Clin Chem 2002, 48(3):421-427.
143. Esteller M., et al. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 1999, 59(1):67-70.
144. Ulivi P., et al. P16INK4A and CDH13 hypermethylation in tumor and serum of non-small cell lung cancer patients. J Cell Physiol 2006, 206(3):611-615.
145. Fujiwara K., et al. Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Clin Cancer Res 2005, 11(3):1219-1225.
146. Zhang Y., et al. Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer. Cancer Lett 2011, 303(1):21-28.
147. Esposito A., et al. Monitoring tumor-derived cell-free DNA in patients with solid tumors: clinical perspectives and research opportunities. Cancer Treat Rev 2014, 40(5):648-655.
148. Ulivi P., Silvestrini R. Role of quantitative and qualitative characteristics of free circulating DNA in the management of patients with non-small cell lung cancer. Cell Oncol (Dordr) 2013, 36(6):439-448.
149. Alix-Panabieres C., Schwarzenbach H., Pantel K. Circulating tumor cells and circulating tumor DNA. Annu Rev Med 2012, 63:199-215.
150. Narayan A., et al. Ultrasensitive measurement of hotspot mutations in tumor DNA in blood using error-suppressed multiplexed deep sequencing. Cancer Res 2012, 72(14):3492-3498.
151. Weber B., et al. Complete pathologic response in lung tumors in two patients with metastatic non-small cell lung cancer treated with erlotinib. J Thorac Oncol 2011, 6(11):1946-1949.
152. Punnoose E.A., et al. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin Cancer Res 2012, 18(8):2391-2401.
153. Olive V., Jiang I., He L. Mir-17-92, a cluster of miRNAs in the midst of the cancer network. Int J Biochem Cell Biol 2010, 42(8):1348-1354.
154. Tanzer A., Stadler P.F. Molecular evolution of a microRNA cluster. J Mol Biol 2004, 339(2):327-335.
155. Volinia S., et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006, 103(7):2257-2261.
156. Garofalo M., et al. MiR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 2009, 16(6):498-509.
157. Boeri M., Pastorino U., Sozzi G. Role of microRNAs in lung cancer: microRNA signatures in cancer prognosis. Cancer J 2012, 18(3):268-274.
158. Mitchell P.S., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008, 105(30):10513-10518.
159. Turchinovich A., et al. Characterization of extracellular circulating microRNA. Nucleic Acids Res 2011, 39(16):7223-7233.
160. Roa W.H., et al. Sputum microRNA profiling: a novel approach for the early detection of non-small cell lung cancer. Clin Invest Med 2012, 35(5):E271.
161. Chen L., Jin H. MicroRNAs as novel biomarkers in the diagnosis of non-small cell lung cancer: a meta-analysis based on 20 studies. Tumour Biol 2014, 35(9):9119-9129.
162. Lebanony D., et al. Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J Clin Oncol 2009, 27(12):2030-2037.
163. Bishop J.A., et al. Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach. Clin Cancer Res 2010, 16(2):610-619.
164. Barbareschi M., et al. Heterogeneity of large cell carcinoma of the lung: an immunophenotypic and miRNA-based analysis. Am J Clin Pathol 2011, 136(5):773-782.
165. Akerley W.L., et al. The impact of serum based proteomic mass spectrometry test on treatment recommendations in advanced non small cell lung cancer. Curr Med Res Opin 2013.
166. Kuiper J.L., et al. VeriStrat((R)) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib. Br J Cancer 2012, 107(11):1820-1825.
167. Sun W., et al. Predictive value of a serum-based proteomic test in non-small-cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitors: a meta-analysis. Curr Med Res Opin 2014, 1-7.
168. Zhang Q., et al. EGFR mutations and clinical outcomes of chemotherapy for advanced non-small cell lung cancer: a meta-analysis. Lung cancer 2014.
169. Taguchi A., et al. Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell 2011, 20(3):289-299.
170. Pernemalm M., et al. Use of narrow-range peptide IEF to improve detection of lung adenocarcinoma markers in plasma and pleural effusion. Proteomics 2009, 9(13):3414-3424.
171. Carraresi L., et al. Establishment and characterization of murine small cell lung carcinoma cell lines derived from HPV-16 E6/E7 transgenic mice. Cancer Lett 2006, 231(1):65-73.
172. Yu L., et al. Identification of ENO1 as a potential sputum biomarker for early-stage lung cancer by shotgun proteomics. Clin Lung Cancer 2014, 15(5):372 e1-378 e1.
173. Krebs M.G., et al. Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches. J Thorac Oncol 2012, 7(2):306-315.
174. Hiltermann T.J., et al. Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor. Ann Oncol 2012, 23(11):2937-2942.
175. Hou J.M., et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol 2012, 30(5):525-532.
176. Chen T.F., et al. CK19 mRNA expression measured by reverse-transcription polymerase chain reaction (RT-PCR) in the peripheral blood of patients with non-small cell lung cancer treated by chemo-radiation: an independent prognostic factor. Lung Cancer 2007, 56(1):105-114.
177. Pirozzi G., et al. Prognostic value of cancer stem cells, epithelial-mesenchymal transition and circulating tumor cells in lung cancer. Oncol Rep 2013.
178. Marchetti A., et al. Assessment of EGFR Mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment. PLoS One 2014, 9(8):e103883.
179. Hodgkinson C.L., et al. Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nat Med 2014, 20(8):897-903.
180. Wu C., et al. Preliminary investigation of the clinical significance of detecting circulating tumor cells enriched from lung cancer patients. J Thorac Oncol 2009, 4(1):30-36.
181. Chen Q., et al. Lung cancer circulating tumor cells isolated by the EpCAM-independent enrichment strategy correlate with Cytokeratin 19-derived CYFRA21-1 and pathological staging. Clin Chim Acta 2013, 419:57-61.
182. Cheng H.Y., Lai L.J., Ko F.H. Rapid and sensitive detection of rare cancer cells by the coupling of immunomagnetic nanoparticle separation with ELISA analysis. Int J Nanomed 2012, 7:2967-2973.
183. Christoph D.C., et al. Detection of circulating lung cancer cells with strong thymidylate synthase reactivity in the peripheral blood of a patient with pulmonary adenocarcinoma treated with pemetrexed. J Thorac Oncol 2012, 7(4):766-767.
184. Das M., et al. ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy. Lung Cancer 2012, 77(2):421-426.
185. Friboulet L., et al. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med 2013, 368(12):1101-1110.
186. Otto W.R. Lung epithelial stem cells. J Pathol 2002, 197(4):527-535.
187. Giangreco A., et al. Stem cells are dispensable for lung homeostasis but restore airways after injury. Proc Natl Acad Sci USA 2009, 106(23):9286-9291.
188. Giangreco A., Groot K.R., Janes S.M. Lung cancer and lung stem cells: strange bedfellows?. Am J Respir Crit Care Med 2007, 175(6):547-553.
189. Chen K., et al. Dachshund binds p53 to block the growth of lung adenocarcinoma cells. Cancer Res 2013.
190. Konishi J., et al. Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers. Cancer Res 2007, 67(17):8051-8057.
191. Tian F., et al. Effects of the Hedgehog pathway inhibitor GDC-0449 on lung cancer cell lines are mediated by side populations. Clin Exp Med 2012, 12(1):25-30.
192. Lin C., et al. Alveolar type II cells possess the capability of initiating lung tumor development. PLoS One 2012, 7(12):e53817.
193. Mainardi S., et al. Identification of cancer initiating cells in K-Ras driven lung adenocarcinoma. Proc Natl Acad Sci USA 2014, 111(1):255-260.
194. Seo D.C., et al. Gene expression profiling of cancer stem cell in human lung adenocarcinoma A549 cells. Mol Cancer 2007, 6:75.
195. Wang H.W., et al. Reversal of inflammation-associated dihydrodiol dehydrogenases (AKR1C1 and AKR1C2) overexpression and drug resistance in nonsmall cell lung cancer cells by wogonin and chrysin. Int J Cancer 2007, 120(9):2019-2027.
196. Gene Expression Omnibus. Available from: [<>]. http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE1323.
197. Desai T.J., Brownfield D.G., Krasnow M.A. Alveolar progenitor and stem cells in lung development, renewal and cancer. Nature 2014, 507(7491):190-194.
198. Mukhametshina R.T., et al. Quantitative proteome analysis of alveolar type-II cells reveals a connection of integrin receptor subunits beta 2/6 and WNT signaling. J Proteome Res 2013, 12(12):5598-5608.
199. Chen W.J., et al. Cancer-associated fibroblasts regulate the plasticity of lung cancer stemness via paracrine signalling. Nat Commun 2014, 5:3472.
200. Westhoff B., et al. Alterations of the Notch pathway in lung cancer. Proc Natl Acad Sci USA 2009, 106(52):22293-22298.
201. Zhang S., et al. Inhibition of CK2alpha down-regulates Notch1 signalling in lung cancer cells. J Cell Mol Med 2013, 17(7):854-862.
202. Yoshida T., et al. Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer. Clin Cancer Res 2014, 20(15):4059-4074.
203. Ross H.J., et al. Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer. Clin Cancer Res 2010, 16(6):1938-1949.
204. Kohler J., Schuler M. LUX-Lung 3: redundancy, toxicity or a major step forward? Afatinib as front-line therapy for patients with metastatic EGFR-mutated lung cancer. Future Oncol 2014, 10(4):533-540.
205. Planchard D. Identification of driver mutations in lung cancer: first step in personalized cancer. Target Oncol 2013, 8(1):3-14.
206. Rekhtman N., et al. Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma. Mod Pathol 2013, 26(4):511-522.
207. Arcila M.E., et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther 2013, 12(2):220-229.
208. Bianchi F., et al. A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Mol Med 2011, 3(8):495-503.
209. Shen J., et al. Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers. BMC Cancer 2011, 11:374.
210. Boeri M., et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci USA 2011, 108(9):3713-3718.
211. Chen X., et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008, 18(10):997-1006.
212. Hu Z., et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 2010, 28(10):1721-1726.
213. Shen J., et al. Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab Invest 2011, 91(4):579-587.
214. Silva J., et al. Vesicle-related microRNAs in plasma of nonsmall cell lung cancer patients and correlation with survival. Eur Respir J 2011, 37(3):617-623.
215. Foss K.M., et al. MiR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer. J Thorac Oncol 2011, 6(3):482-488.
216. Rabinowits G., et al. Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer 2009, 10(1):42-46.